2024
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial
Qadri F, Khanam F, Zhang Y, Biswas P, Voysey M, Mujadidi Y, Kelly S, Bhuiyan A, Rajib N, Hossen I, Rahman N, Islam S, Pitzer V, Kim Y, Clemens J, Pollard A, Liu X. 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial. The Lancet 2024, 404: 1419-1429. PMID: 39396349, DOI: 10.1016/s0140-6736(24)01494-6.Peer-Reviewed Original ResearchConceptsTyphoid conjugate vaccineJapanese encephalitis vaccineVaccine effectivenessRandomised controlled trialsConjugate vaccineFollow-upTyphoid feverControlled trialsVaccine protectionChildren aged 9 monthsIncreased risk of typhoid feverAnti-Vi IgGRisk of typhoid feverVaccine efficacy dataTest-negative designAged 9 monthsUnvaccinated individualsHigh-burden countriesIncidence rate ratiosAnalyses of vaccine effectivenessSingle-doseSingle doseDecay of antibodiesSubgroup analysisBooster doseCelebrating a body of work
Papin J, Mac Gabhann F, Pitzer V. Celebrating a body of work. PLOS Computational Biology 2024, 20: e1012441. PMID: 39325699, PMCID: PMC11426496, DOI: 10.1371/journal.pcbi.1012441.Peer-Reviewed Original ResearchGenome-wide association study between SARS-CoV-2 single nucleotide polymorphisms and virus copies during infections
Li K, Chaguza C, Stamp J, Chew Y, Chen N, Ferguson D, Pandya S, Kerantzas N, Schulz W, Initiative Y, Hahn A, Ogbunugafor C, Pitzer V, Crawford L, Weinberger D, Grubaugh N. Genome-wide association study between SARS-CoV-2 single nucleotide polymorphisms and virus copies during infections. PLOS Computational Biology 2024, 20: e1012469. PMID: 39288189, PMCID: PMC11432881, DOI: 10.1371/journal.pcbi.1012469.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesSingle-nucleotide polymorphismsAssociation studiesWhole-genome sequencingAmino acid changesSingle nucleotide polymorphismsPairs of substitutionsViral copiesEpistasis testsGenome sequenceGenetic variationSpike geneAcid changesViral genomeNucleotide polymorphismsSARS-CoV-2Detect interactionsHost factorsVirus copiesCopyInfection dynamicsRT-qPCRPolymorphismOmicron BASARS-CoV-2 infectionGlobal patterns of rebound to normal RSV dynamics following COVID-19 suppression
Thindwa D, Li K, Cooper-Wootton D, Zheng Z, Pitzer V, Weinberger D. Global patterns of rebound to normal RSV dynamics following COVID-19 suppression. BMC Infectious Diseases 2024, 24: 635. PMID: 38918718, PMCID: PMC11201371, DOI: 10.1186/s12879-024-09509-4.Peer-Reviewed Original ResearchExpanded Programme on Immunization at 50 years: its legacy and future
Wahl B, Pitzer V. Expanded Programme on Immunization at 50 years: its legacy and future. The Lancet 2024, 403: 2265-2267. PMID: 38796196, DOI: 10.1016/s0140-6736(24)00982-6.Peer-Reviewed Original ResearchEstimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study
Hartner A, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, de Villiers M, Ferrari M, Fraser K, Fu H, Hallett T, Hinsley W, Jit M, Karachaliou A, Moore S, Nayagam S, Papadopoulos T, Perkins T, Portnoy A, Minh Q, Vynnycky E, Winter A, Burrows H, Chen C, Clapham H, Deshpande A, Hauryski S, Huber J, Jean K, Kim C, Kim J, Koh J, Lopman B, Pitzer V, Tam Y, Lambach P, Sim S, Woodruff K, Ferguson N, Trotter C, Gaythorpe K. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study. The Lancet Global Health 2024, 12: e563-e571. PMID: 38485425, PMCID: PMC10951961, DOI: 10.1016/s2214-109x(23)00603-4.Peer-Reviewed Original ResearchConceptsCatch-up activitiesVaccine-preventable disease burdenCatch-upVaccine Impact Modelling ConsortiumImmunisation servicesMiddle-income countriesEffectiveness of HPV vaccinationVaccine effectivenessAffected cohortBill & Melinda Gates FoundationImmunisation coverageLow-incomeLong-term effectsWHO-UNICEFDisease burdenVaccination coverageCalendar yearImmunisation effortsMelinda Gates FoundationMitigation measuresCountriesYears of vaccinationYellow fever vaccine
2023
Typhoid fever
Meiring J, Khanam F, Basnyat B, Charles R, Crump J, Debellut F, Holt K, Kariuki S, Mugisha E, Neuzil K, Parry C, Pitzer V, Pollard A, Qadri F, Gordon M. Typhoid fever. Nature Reviews Disease Primers 2023, 9: 71. PMID: 38097589, DOI: 10.1038/s41572-023-00480-z.Peer-Reviewed Original ResearchConceptsTyphoid feverUndifferentiated febrile illnessInvasive bacterial diseaseEffective vaccination programsFecal-oral routeNovel diagnostic modalitiesFebrile illnessBloodstream infectionsVaccination programBlood culturesClinical trialsImmunological protectionHigh burdenCausative organismDiagnostic modalitiesGlobal burdenDisease pathogenesisFeverHuman infectionsIntestinal epitheliumYoung adultsCulture testingSalmonella enterica subspSerovar TyphiAntimicrobial resistanceIncorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines
Prunas O, Willemsen J, Bont L, Pitzer V, Warren J, Weinberger D. Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines. Epidemiology 2023, 35: 103-112. PMID: 37793120, DOI: 10.1097/ede.0000000000001680.Peer-Reviewed Original ResearchFloods and Diarrhea Risk in Young Children in Low- and Middle-Income Countries
Wang P, Asare E, Pitzer V, Dubrow R, Chen K. Floods and Diarrhea Risk in Young Children in Low- and Middle-Income Countries. JAMA Pediatrics 2023, 177: 1206-1214. PMID: 37782513, PMCID: PMC10546297, DOI: 10.1001/jamapediatrics.2023.3964.Peer-Reviewed Original ResearchConceptsMiddle-income countriesDiarrhea riskOdds ratioMAIN OUTCOMEMixed-effects logistic regression modelRisk of diarrheaCross-sectional studyHigher odds ratioPrevalence of diarrheaLogistic regression modelsHealth survey programUnexposed childrenEffect modificationChild healthDiarrhea prevalenceSurvey clustersSignificant associationHygiene practicesFourth weekWeeksStrong associationRandom interceptYoung childrenChildrenDiarrheaAssessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi
Walker J, Chaguza C, Grubaugh N, Carey M, Baker S, Khan K, Bogoch I, Pitzer V. Assessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi. Nature Communications 2023, 14: 6502. PMID: 37845201, PMCID: PMC10579367, DOI: 10.1038/s41467-023-42353-9.Peer-Reviewed Original ResearchConceptsXDR S. TyphiS. typhiDrug-resistant Salmonella enterica serovar TyphiDrug-resistant Salmonella TyphiTyphoid outbreakMajor public health threatResistant Salmonella typhiPublic health activitiesTyphoid fever incidencePublic health threatSalmonella enterica serovar TyphiXDR typhoidEnterica serovar TyphiH58 haplotypeHigh riskOnward transmissionTyphoid feverSignificant associationHealth activitiesFever incidenceHealth threatFuture outbreaksSerovar TyphiSalmonella typhiTyphiYear-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study
Löwensteyn Y, Zheng Z, Rave N, Bannier M, Billard M, Casalegno J, Pitzer V, Wildenbeest J, Weinberger D, Bont L, Putten M, Smit-Kleinlugtenbeld E, Peetsold M, van der Kuip M, van Goudoever H, van Keulen B, Boot A, Kloos R, van Gool S, Snepvangers Y, Kuijpers A, Menelik N, de Crom S, Miedema C, Tusscher G, van Giessen J, de Moor R, Faber M, Breukels M, Jaddoe V, Duijts L, Lutterman C, Vink I, Tramper-Stranders G, Oudshoorn A, Ritman A, Dubbink-Verheij G, Bolt J, Cakir C, Rietveld E, Bekhof J, Rings E, de Swart J, Driessen G, Doedens R, Nijssen L, van Onzenoort-Bokken L, Meijneke R, van Scherpenzeel M, Faber T, de Groof F, Schouten S, van de Zande J, de Coul M, Henriet S, Stol K, van Rossem M, Jacobs M, van Houten M, Zuurbier R, Plötz F, de Vries A, van der Heide R, van Boekholt A, de Jong G, Rashid A, Roelofs M, Illy K, Reijmerink N, van Dorth S, Schipper S, Rosias P, Teirlinck A. Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study. The Journal Of Infectious Diseases 2023, 228: 1394-1399. PMID: 37477906, PMCID: PMC10640768, DOI: 10.1093/infdis/jiad282.Peer-Reviewed Original ResearchChanges in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited StatesCost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitionsPlanning for Mpox on a College Campus: A Model-Based Decision-Support Tool.
Savinkina A, Chitwood M, Kwon J, Pitzer V, Gonsalves G, Paltiel A. Planning for Mpox on a College Campus: A Model-Based Decision-Support Tool. Annals Of Internal Medicine 2023, 176: 340-347. PMID: 36716454, PMCID: PMC10338074, DOI: 10.7326/m22-2734.Peer-Reviewed Original ResearchConceptsSustained transmissionNational InstituteLow-risk groupHigh-risk populationPopulation of MSMHealth-National InstituteResidential college campusSymptomatic casesHypothetical cohortCongregate settingsStudy populationPreemptive vaccinationReactive vaccinationInfectious diseasesVaccinationDrug abuseBasic reproductive numberFuture outbreaksFrequent physical contactMSMReproductive numberOutbreakDaysMenTimely detection
2022
Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness
Burrows H, Antillón M, Gauld J, Kim J, Mogasale V, Ryckman T, Andrews J, Lo N, Pitzer V. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine 2022, 41: 965-975. PMID: 36586741, PMCID: PMC9880559, DOI: 10.1016/j.vaccine.2022.12.032.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioRoutine vaccinationVaccine impactPublic health impactOne-time catchPotential public health impactHigh-incidence settingsTyphoid fever casesCost-effectiveness ratioMonths of ageHealth impactsModel-predicted outcomesPrimary outcomeChronic carriersIncidence settingsSymptomatic casesVaccine introductionEndemic settingsVaccine deploymentFever casesVaccinationTyphoid casesIncremental costTyphoid transmissionMonthsWaning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Prunas O, Weinberger D, Pitzer V, Gazit S, Patalon T. Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel. Clinical Infectious Diseases 2022, 76: 113-118. PMID: 36484301, PMCID: PMC10202431, DOI: 10.1093/cid/ciac315.Peer-Reviewed Original ResearchConceptsMaccabi Healthcare ServicesBNT162b2 vaccineSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionPositive polymerase chain reaction testSARS-CoV-2 infectionPfizer BNT162b2 vaccineCoronavirus 2 infectionVaccine-induced immunityVaccine-induced protectionPolymerase chain reaction testIncidence of infectionCoronavirus disease 2019COVID-19Chain reaction testShort-term effectivenessCase-control designLong-term effectivenessVaccine effectivenessSymptomatic infectionLong-term protectionDisease 2019Delta variantPredicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis
Kraay A, Steele M, Baker J, Hall E, Deshpande A, Saidzosa B, Mukaratirwa A, Boula A, Mpabalwani E, Kiulia N, Tsolenyanu E, Enweronu-Laryea C, Abebe A, Beyene B, Tefera M, Willilo R, Batmunkh N, Pastore R, Mwenda J, Antoni S, Cohen A, Pitzer V, Lopman B. Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis. Vaccine 2022, 40: 6631-6639. PMID: 36210251, PMCID: PMC10351612, DOI: 10.1016/j.vaccine.2022.09.072.Peer-Reviewed Original ResearchConceptsRotavirus vaccinationRotavirus positivityVaccine introductionOne-dose scheduleTwo-dose seriesRotavirus burdenRotavirus casesRotavirus gastroenteritisHospital admissionMiddle-income countriesVaccine impactVaccinated individualsLong-term impactMortality burdenPercent reductionVaccinationLife yearsIndirect protectionLow-income countriesLong-term magnitudePositivityDeathBurdenYearsIntroduction Data
2020
Meeting Report: WHO Workshop on modelling global mortality and aetiology estimates of enteric pathogens in children under five. Cape Town, 28–29th November 2018
Prudden H, Hasso-Agopsowicz M, Black R, Troeger C, Reiner R, Breiman R, Jit M, Kang G, Lamberti L, Lanata C, Lopman B, Ndifon W, Pitzer V, Platts-Mills J, Riddle M, Smith P, Hutubessy R, Giersing B. Meeting Report: WHO Workshop on modelling global mortality and aetiology estimates of enteric pathogens in children under five. Cape Town, 28–29th November 2018. Vaccine 2020, 38: 4792-4800. PMID: 32253097, PMCID: PMC7306158, DOI: 10.1016/j.vaccine.2020.01.054.Peer-Reviewed Original ResearchConceptsNumber of deathsWorld Health OrganizationEnteric diseaseEnteric pathogensVaccine Advisory CommitteeDifferent enteric pathogensDisease burden estimatesJohns Hopkins Bloomberg SchoolVaccine introduction decisionsVaccine product developmentMiddle-income countriesMortality estimatesVaccine prioritizationBurden estimatesGlobal burdenGlobal mortalityDisease estimatesBloomberg SchoolWorking GroupMajor causeHealth OrganizationHealth metricsIndependent working groupEstimation groupDeath
2018
Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction
Bennett A, Pollock L, Jere K, Pitzer V, Parashar U, Tate J, Heyderman R, Mwansambo C, French N, Nakagomi O, Iturriza-Gomara M, Everett D, Cunliffe N, Bar-Zeev N, Consortium F. Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction. Vaccine 2018, 36: 7142-7148. PMID: 29887320, PMCID: PMC6238204, DOI: 10.1016/j.vaccine.2018.04.030.Peer-Reviewed Original ResearchConceptsPost-vaccine introductionPrevalence of rotavirusVaccine effectivenessRotavirus prevalenceAcute gastroenteritisVaccine introductionRotavirus hospitalisationsVaccine coverageEfficacy estimatesAdjusted vaccine effectivenessRotavirus vaccine introductionYears of ageUse of vaccinesUnvaccinated infantsRotavirus diarrheaRotavirus diseaseUnvaccinated childrenReferral hospitalRoutine immunisationMalawian childrenSevere diarrheaStool samplesImportant causePoisson regressionHospitalisation
2017
The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK
Meiring J, Gibani M, Group: T, Basnyat, Bentsi-Enchill A, Clemens J, Darton T, Date K, Dougan G, Garrett D, Gessner B, Gordon M, Heyderman R, Hombach J, Kotloff K, Levine M, Luby S, Mohan V, Marfin A, Mulholland K, Neuzil K, Pitzer V, Pollard A, Qadri F, Salisbury D, Zaidi A. The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK. Vaccine 2017, 35: 5081-5088. PMID: 28802757, DOI: 10.1016/j.vaccine.2017.08.001.Peer-Reviewed Original ResearchConceptsTyphoid Vaccine Acceleration ConsortiumEffectiveness study designStudy designImportant public health toolIntroduction of TCVsHigh disease burdenStrategic Advisory GroupPublic health toolGAVI-eligible countriesCost-effectiveness analysisIntroduction of typhoidEnteric feverPrevious vaccinesTyphoid vaccineDisease burdenEfficacious vaccineGlobal burdenCountry-level decisionsTyphoid epidemiologyTyphoid feverLatest evidenceVaccineTyphoid surveillanceEffectiveness studiesHealth tools